🔬💙 Rare diseases affect 300M people. At Lund Stem Cell Center, our researchers are working to change that.
For Assoc. Prof. Johan Flygare, two decades of #DBA research led to Apriligen, a company developing a #GeneTherapy for this rare blood disorder.
Read more this #RareDiseaseDay ⤵️
For Assoc. Prof. Johan Flygare, two decades of #DBA research led to Apriligen, a company developing a #GeneTherapy for this rare blood disorder.
Read more this #RareDiseaseDay ⤵️
Reposted from
Lund Stem Cell Center
💡Associate Prof. Johan Flygare’s research on Diamond-Blackfan Anemia led to the company Apriligen, co-founded with CEO Nicholas Vita. They are developing a #GeneTherapy that is nearing clinical trials.
Read more about their journey from science to startup ⤵️
www.stemcellcenter.lu.se/article/scie...
Read more about their journey from science to startup ⤵️
www.stemcellcenter.lu.se/article/scie...
Comments